An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 22 Sep 2017 Planned number of patients changed from 30 to 33.
- 22 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
- 22 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.